Exciting to see KaNDy Therapeutics listed as one of the seven European #FemTech companies aiming to reclaim the discussion and champion #womenshealth You can read the full article below. #nonhormonal #menopause

Great to have our Co-founder and CEO, Dr Mary Kerr, featured in this months’ @ConsiliumHC newsletter. You can read the full interview here bit.ly/2UJMQLE

Big step forward for midlife women’s health treatment options - non- hormonal and highly effective treatment for hot flushes day and night read ncbi.nlm.nih.gov/pubmed/32068688

We are very pleased to announce that data from our RELENT-1 study with non-hormonal drug candidate, NT-814, has been published in the Menopause Journal. Read more here: bit.ly/38O9cQa

Many women at the peak of their careers consider leaving their job because of menopause symptoms.

There are 61 million women over the age of 50 in the U.S. workforce - the fastest growing portion of the U.K. workforce

"Menopause is one of the strongest, most impactful, and most discriminatory taboos still existing in the workplace."

The menopause affects all women, but a lack of understanding means that many aren't getting the help they need. A new survey has revealed that even some medical professionals don't have the necessary knowledge of the subject. Mumsnet | 50Sense (LizzieCarrEllis) | @Dianedanz

Interesting article in the Mail+ discussing how 1 in 4 women suffering from the #menopause feel ignored by doctors. More awareness about the condition is needed to provide patients the help they need dailym.ai/382zNYO

Today we celebrate International Women’s Day and shine a spotlight on women’s achievements. This year’s theme focuses on the difference individuals can make to collectively help create a gender equal world, a statement we certainly support #EachforEqual #IWD2020

Today we also want to raise awareness about the debilitating symptoms of the #menopause as women of menopause age are the fastest growing portion of the UK workforce. We are aiming to tackle this problem with our #nonhormonal drug candidate, NT-814 bit.ly/2IlVFnw #IWD

Mary Kerr CEO of KaNDy Therapeutics & #NeRReTherapeutics has not let doubt deter her in her quest to bring a #treatment for symptoms of #menopause to the market ow.ly/I1DS30qpqtH #menopausematters #womenshealth #womenleaders #orgasmicleadership #femalefounders #investinwomen

According to the #DelveInsight estimate, #Vasomotor Symptoms #Market Size is expected to grow at a #CAGR of 7%. Some of the Major Players in the #VasomotorSymptoms Market include #FerventPharma, @AstellasEurope, KaNDy Therapeutics, #MithraPharma and others. lnkd.in/g6qugPf

Editor’s Pick: Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal #women: a placebo-controlled, randomized clinical trial bit.ly/2z2U8kN The Menopause Society life #menopause

You can now read our accepted ENDO 2020 SWITCH-1 abstract discussing the unique findings from a Phase 2b study with NT-814. Significant improvement in hot flash frequency, sleep, mood and quality of life were seen. #menopause #nonhormonal bit.ly/2zETw5m

Our ENDO 2020 abstract showing that NT-814 has potential to treat endometriosis and uterine fibroids through modulation of oestrogen is now published in the Journal of the Endocrine Society. #endometriosis #uterinefibroids Read more: bit.ly/3bunIwZ

VCs are finally ready to talk about menopause | PitchBook pitchbook.com/news/articles/… via PitchBook News

30% of women with symptoms of #menopause have found their symptoms worsen during #COVID19 bit.ly/2NhbQ7R Read our abstract published in Endocrine Society to learn more about our #nonhormonal approach to tackle distressing symptoms of the menopause bit.ly/3drWFDA

Bayer to acquire UK-based biotech KaNDy Therapeutics Ltd bit.ly/2PThxdO

Encouraging news out from the BBC today, as #menopause is added to the school curriculum for the first time. Watch the below video for more information. bbc.in/2EJ19dv